Friday, 9 September 2016

ILCA Symposium 2: Controversies in Liver Cancer (Pros and Cons Session)

Chairs: Masatoshi Kudo, MD, PhD (Japan) and Kwang-Hyub Han, MD (Republic of Korea) 

  • Bruno Sangro, MD, PhD (Spain)

    Transarterial chemoembolization (TACE) and Y90-radioembolization (Y90) are at the core of the treatment of patients with hepatocellular carcinoma who cannot receive potentially curative therapies such as transplantation, resection or percutaneous ablation.

  • Valérie Vilgrain, PhD (France)

    Transarterial chemoembolization (TACE) and Y90 selective intra-arterial radiation therapy (SIRT) also named radioembolization are both intra-arterial treatments of liver cancer requiring selective catheterisation of intrahepatic arterial branches.

  • Ann-Lii Cheng, MD, PhD (Taiwan)

    Similar to many other cancer types, HCC has modest, yet definite response to immune checkpoint inhibitors. This finding is particularly significant in HCC which, for 8 years, has been faltering in drug development.

  • Jordi Bruix, MD, PhD (Spain)

    Systemic treatment of hepatocellular carcinoma has been a very disappointing field until very recently. The success of sorafenib was a landmark result that showed that years of research in methodology and molecular targets pay off.

  • Gonzalo Sapisochin, MD (Canada)

    Liver transplantation (LT) is the best treatment option for patients with selected hepatocellular carcinoma (HCC). The Milan criteria1 moved the field forward and set the bar for LT for HCC.

  • Francis Yao, MD (USA)

    The Milan criteria have been the benchmark for the selection of candidates with hepatocellular carcinoma (HCC) for liver transplant (LT) for the past 2 decades.

  • Richard Kinh Gian Do, MD, PhD (USA)

    Response evaluation in clinical trials for patients with solid tumours is based on one-dimensional measurements of tumour size over the course of treatment.

  • Haesun Choi, MD (USA)

    Traditionally, response evaluation of solid tumour has been based on the changes in tumour size over time.